Mycophenolate Mofetil for Reducing Cardiovascular Risk in Renal Transplant Recipients (MMCR)

A 6-month, Prospective, Open-label, Randomized, Controlled, Pilot Study Evaluating the Efficacy, Safety and Toxicity of an Optimized Immunosuppressive Regimen of CellCept (Mycophenolate Mofetil, MMF) and Reduced Doses of Both Calcineurin-inhibitors and Prednisone in Renal Transplant Recipients With an Increased 10-year Coronary Heart Disease Risk

The purpose of this research study is to determine if adding or increasing the dose of CellCept while lowering the dose of tacrolimus (Prograf or Advagraf) or cyclosporine (Neoral), and/or steroids can reduce the likelihood of developing coronary heart disease in the next 10 years.

The investigators will calculate the change in risk of developing coronary heart disease using the Framingham score. The Framingham score is a mathematical equation that includes the following information: Age, Gender, Diabetes status, Smoking status, Lipids, Blood Pressure. The Framingham score estimates how likely it is that someone will develop coronary heart disease over the next 10 years.

Study Overview

• Status: Terminated
• Conditions: Cardiovascular Diseases; Kidney Transplantation
• Intervention / Treatment: Drug: mycophenolate mofetil; Other: standard immunosuppression

Detailed Description

Kidney transplant recipients are required to take medications called immunosuppressants to lower their immune systems to help protect the donated kidney. The medications have improved over the years and as a result the donated kidneys are generally working longer. This allows the Transplant Team to focus more on the long term complications of kidney transplantation such as cardiovascular disease.

There have been few prospective (looking forward) research studies looking at kidney transplant recipient cardiovascular risk factors after transplant.

We know that immunosuppressive medications have a number of serious side effects that can increase cardiovascular disease risk factors such as high blood pressure, high lipids (fats in the blood), and high blood sugar. Medications such as tacrolimus, cyclosporine and prednisone work well to protect the donated kidney but are also known to increase the risk of developing or worsening cardiovascular disease.

CellCept is another type of immunosuppressive agent. CellCept is not associated as much with the risk of developing cardiovascular disease.

This is a pilot study being done to collect information about cardiovascular risk factors in kidney transplant recipients and to see if adjusting the immunosuppressive medications can help to lower the overall risk for developing heart disease in the future.

This research study plans to enroll 45 participants from 2 different transplant centres in Canada: St. Michael's Hospital in Toronto and St. Paul's Hospital in Saskatoon. The study duration is approximately 7 months per participant. The study will be looking for participants who are 30 years of age or older and who are at least 6 months after the transplant operation.

• Study Type: Interventional
• Enrollment (Actual): 2
• Phase: Phase 3

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Toronto, Ontario, Canada, M5C 2T2
      • St. Michael's Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 30 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Renal transplant recipients who are ≥ 6 months post-day of transplant surgery.
2. Single organ kidney recipient (may be for first or repeat transplant).
3. Age ≥ 30 years of age as of the Day 0 visit.
4. Immunosuppressive regimen consisting of a CNI (cyclosporine [CsA, Neoral] or tacrolimus [TAC, Prograf or Advagraf], corticosteroids and either MMF (CellCept), EC-MPS (Myfortic), AZA (Imuran) or SRL (Rapamune) at the baseline visit. Patients are to be maintained on the same dose(s) for at least 4 weeks prior to study enrolment.
5. If the patient is taking an MPA immunosuppressant at the time of the screening visit, the MMF (CellCept) dose must be ≤ 1500 mg/day; or the EC-MPS (Myfortic) dose must be ≤ 1080 mg/day.
6. Framingham risk factor score that exceeds the low comparative 10-year CHD risk, based on age and gender.

7. Presence of at least one established CV risk factor at baseline warranting modification of the immunosuppressive regimen including:

   • Hypertension: Blood pressure ≥ 140 mmHg systolic and/or ≥ 90 mmHg diastolic and/or requiring ≥ 1 antihypertensive medication.
   • Diabetes mellitus: Established diabetes requiring treatment with oral hypoglycemic agents or insulin, or known IFG or IGT based on 75-g oral glucose tolerance testing (2003 Canadian Diabetes Association criteria).
   • Hyperlipidemia: TC ≥ 5.2 mmol/L, or LDL-C ≥ 2.6 mmol/L, or TG ≥ 1.7 mmol/L, or TC:HDL ≥ 4 and/or requiring ≥ 1 anti-hyperlipidemia agent.
8. Willingness and ability to complete protocol requirements.
9. Written informed consent.

Exclusion Criteria:

1. Contraindication to receiving MMF (CellCept) or increasing CellCept dose.
2. Clinically suspected acute rejection (AR) or BPAR within 3 months prior to the baseline visit.
3. Proteinuria ≥ 1 g/24 hours
4. Treatment with AZA (Imuran), EC-MPS (Myfortic) or SRL (Rapamune) and patient or physician decision not to discontinue these agents and switch to MMF (CellCept) at the time of randomization.
5. MDRD (4-variable) eGFR < 15 mL/min/1.73 m2
6. Patients who currently exceed thresholds for plasma glucose, cholesterol or blood pressure. Patients may be re-considered 1 month after the treatment is in place and no further therapeutic changes are anticipated.
7. Patients who require changes to their blood pressure, blood sugar or blood lipid management between the Screening Visit and Day 0. Patients may be re-considered 1 month after the adjusted treatment is in place and no further therapeutic changes are anticipated.
8. Pregnancy, lactation or (for women of childbearing potential) inability or decision not to use a reliable method of contraception for the entire study duration.
9. Active infection requiring treatment.
10. Treatment with unlicensed investigational drugs, devices or other prohibited medications - see Section 4.4.1
11. Participation in any other interventional clinical trial during the previous 4 weeks or during this trial.
12. History of malignancy, other than non-melanoma skin cancer that has been totally excised and has not recurred for >2 years.
13. History of psychological illness or condition that could interfere with the patient's ability to understand or comply with the study requirements.

14. Presence of other significant diseases or issues which, in the opinion of the sponsor-investigator, may:

    • Put the patient at risk as a result of study participation
    • Influence the study result
    • Affect the patient's ability to participate in the study
    • Require a change in immunosuppression medication used or a dose change within the next 6 months (unstable renal function, gout that may require treatment with prednisone, etc)
    • Reduce life expectancy. Examples include but are not limited to history of noncompliance and transportation issues that could affect a participant's ability to successfully complete the study requirements. Inability or refusal to provide blood samples, end-stage disease of organs such as lung, liver or heart.
15. Exclusion of patients who are hypersensitive to CellCept (mycophenolate mofetil), mycophenolic acid or any component of the drug).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Control	Other: standard immunosuppression; Current immunosuppressive therapy will be maintained throughout the study unless a change is required for safety reasons.
Experimental: CellCept optimization	Drug: mycophenolate mofetil; Introduction of CellCept or increase in the dose of CellCept to a maximum of 2 g/day. In patients not already receiving CellCept, azathioprine (AZA), enteric-coated mycophenolate sodium (EC-MPS) or sirolimus (SRL) will be discontinued and replaced by CellCept in divided doses to a maximum of 2 g/day. CNI doses will be reduced to conform to the target trough levels in the low-dose CNI arms of the ELITE-Symphony study +/- steroid dose reduction. Any CNI dose change will require measurement of CNI trough levels at 7 days post dose change +/- 3 days. Target CNI trough levels in the Symphony study: Low-dose CsA: Initial oral dose of 1-2 mg/kg bid, to achieve a target trough level of 50-100 ng/mL.; Low-dose TAC: Initial oral dose of 0.1 mg/kg/day divided into two doses* with a target trough level of 3-7 ng/mL (*Advagraf may also be used at a dose of 0.1 mg/kg once daily with a target trough level of 3-7 ng/mL); Other Names: CellCept, MMF

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The change in the Framingham 10-yr age and gender adjusted score for coronary heart disease from baseline to Month 6	Baseline to Month 6
The incidence of a composite of acute rejection (clinically suspected and biopsy-proven), graft loss or patient death.	Month 6

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Framingham point total	Change in Framingham point total from baseline to month 6	Baseline to Month 6
Day and night blood pressure	Change in day and night blood pressure (defined by awake and sleep times) measured by 24-hour ambulatory blood pressure monitoring (ABPM) from baseline to month 6	Baseline to Month 6
Glucose metabolism	Change in glucose metabolism, based on HbA1C levels in patients with and without diabetes, and the prevalence of impaired fasting glucose (IFG) and impaired glucose intolerance (IGT) in patients without overt diabetes from baseline/randomization to month 6.	Baseline to Month 6
Lipid metabolism	Change in lipid metabolism, measured by the fasting levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG)and ratio of TC to HDL-C from baseline/randomization to month 6	Baseline to Month 6
Change in renal function	Change in renal function from baseline/randomization to month 6 as measured by serum creatinine, estimated glomerular filtration rate, (MDRD 4-variable equation), change in eGFR slope, change in chronic kidney disease (CKD), 24-hr urine creatinine clearance and protein/albumin excretion	Baseline to Month 6
Adverse cardiovascular events	Proportion of patients who experience any adverse cardiovascular event such as myocardial infarction (MI), percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), fatal and non-fatal cerebrovascular events (including fatal or non-fatal stroke, transient ischemic attack, reversible ischemic neurological deficit and subarachnoid hemorrhage). Cardiovascular events will be adjudicated by a cardiologist blinded to treatment assignment.	Month 6
Highly-sensitive C-reactive protein (CRP) level	Change in highly-sensitive CRP level between randomization and month 6.	Randomization to Month 6
Change in other biomarkers of cardiovascular risk	Change in other biomarkers of cardiovascular risk between randomization and month 6: human adiponectin (including its high molecular weight isoform), uric acid, early morning urine albumin-to-creatinine ratio, B-type (brain) natriuretic peptide (BNP), fibrinogen, D-dimer (fibrin degradation fragment), advanced glycosylation endproduct (AGE), paraoxonase B, cystatin C, insulin, proinsulin, malondialdehyde (MDA), protein carbonyl, glutathione reductase/total and apolipoprotein A1, B and Lp(a).	Randomization to Month 6
Incidence of MMF-attributable adverse events	Incidence of MMF-attributable adverse events including gastrointestinal toxicities, thrombocytopenia, leucopenia and anemia.	Month 6
Additional treatment with cardiovascular co-interventions	Requirements for additional treatment with cardiovascular co-interventions - as per guideline documents.	Month 6
Opportunistic infections	Incidence of opportunistic infections	Month 6
Malignancies	Incidence of malignancies	Month 6
Adverse events	All adverse events (AEs), including clinically significant abnormalities of clinical and laboratory parameters will be captured. Summary statistics will be created for all adverse events and will be summarized by treatment group, by relation to study treatment and seriousness of the event.	Month 6

Collaborators and Investigators

• Sponsor: Ramesh Prasad
• Collaborators: Hoffmann-La Roche
• Investigators: Principal Investigator: Dr. Ramesh Prasad, MBBS MSc, Unity Health Toronto

Study record dates

Study Major Dates

• Study Start: October 1, 2010
• Primary Completion (Actual): October 1, 2011
• Study Completion (Actual): December 1, 2011

Study Registration Dates

• First Submitted: September 28, 2010
• First Submitted That Met QC Criteria: September 30, 2010
• First Posted (Estimate): October 4, 2010

Study Record Updates

• Last Update Posted (Estimate): April 19, 2012
• Last Update Submitted That Met QC Criteria: April 18, 2012
• Last Verified: April 1, 2012

More Information

Terms related to this study

• Keywords: immunosuppression; cardiovascular disease; kidney transplant; mycophenolate mofetil; CellCept; Framingham score
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Enzyme Inhibitors; Antineoplastic Agents; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antitubercular Agents; Antibiotics, Antitubercular; Mycophenolic Acid
• Other Study ID Numbers: ML25073